Weed (BUDZ) 3-Year EBITDA Growth Rate: 3.10% (As of Jun. 2026) — 62% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Weed 3-Year EBITDA Growth Rate?

Weed BUDZ -3.01% 3-Year EBITDA Growth Rate is 3.10% as of Jun. 2026, which is 62% below its 10-year median of 8.10. The stock has 2 warning signs investors should review. Among 810 Drug Manufacturers companies, Weed ranks worse than 62.22% on this metric.

Weed's EBITDA per Share for the three months ended in Jun. 2026 was $-0.00.

During the past 3 years, the average EBITDA Per Share Growth Rate was 3.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Weed was 64.90% per year. The lowest was -130.60% per year. And the median was 8.10% per year.

Weed  (OTCPK:BUDZ) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Weed 3-Year EBITDA Growth Rate Related Terms

BUDZ vs LVRLF, PRFX, SBFM: 3-Year EBITDA Growth Rate Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Weed's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Weed 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Weed's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Weed's 3-Year EBITDA Growth Rate falls into.


Weed 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 3-Year EBITDA Growth Rate of 3.10% mean?
Weed (BUDZ) has a 3-Year EBITDA Growth Rate of 3.10% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Weed and its competitors. This is 62% below median its historical median of 8.10. According to the industry distribution chart, Weed ranks #504 out of 810 companies in the Drug Manufacturers industry, placing it in the top 62.2%.
Is Weed's 3-Year EBITDA Growth Rate too high?
Weed's current 3-Year EBITDA Growth Rate of 3.10% is 62% below median its 10-year median of 8.10. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Weed's value of 3.10% is 65.2% below this industry median. Based on the distribution chart, Weed ranks #504 out of 810 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does Weed's 3-Year EBITDA Growth Rate compare to LVRLF and PRFX?
According to the Drug Manufacturers industry distribution chart, Weed ranks #504 out of 810 companies for 3-Year EBITDA Growth Rate. This places Weed in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Weed's value of 3.10% is 65.2% below this benchmark. While the company's 10-year median is 8.10 vs. the industry median of 8.90, Weed has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Weed's current 3-Year EBITDA Growth Rate of 3.10% is 65.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Weed and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Weed's current 3-Year EBITDA Growth Rate is 3.10%, which is 62% below median its own 10-year median of 8.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Weed stock overvalued right now?
Weed (BUDZ) has a current 3-Year EBITDA Growth Rate of 3.10%. The current 3-Year EBITDA Growth Rate is 3.10%, which is 62% below median its 10-year median of 8.10 and 65.2% below the Drug Manufacturers industry median of 8.90. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Weed (BUDZ), the current 3-Year EBITDA Growth Rate is 3.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Weed Business Description

Address 4920 North Post Trail, Tucson, AZ, USA, 85750
Weed Inc is a bio-pharmaceutical and real estate holding company. The Company focused on asset preservation and the modernization of its business model, including streamlining international operations and exploring the integration of blockchain and AI technologies within the regulated cannabis ecosystem. The Company operates as one reportable segment, which involves the purchase of land and the development of commercial-grade cultivation centers to consult, assist, manage, and lease to licensed dispensary owners and organic grow operators on a contract basis, with a concentration on the legal and medical marijuana sector.